| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D501-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-545 |
| filingDate |
1989-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3da70e0fc22a8cfdf3187b5cc4637fcf |
| publicationDate |
1989-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H01308284-A |
| titleOfInvention |
Ceftazidime pihydrochloride formic acid solvate |
| abstract |
The invention relates to the crystalline formic acid solvate of (6R, 7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetami do]-3-(1-S HY# pyridiniummethyl)ceph-3-em-4-carboxylate dihydrochloride (ceftazidime dihydrochloride). The crystalline solvate is a useful intermediate in the preparation of forms of ceftazidime suitable for administration, e.g. the pentahydrate. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11547707-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8920559-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11274087-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006518713-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8350085-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE49110-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE49302-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8765765-B2 |
| priorityDate |
1988-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |